Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Though lung cancer looks promising a partner is now needed.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
